Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
about
sameAs
Pathogenesis of human immunodeficiency virus infectionFactors in AIDS dementia complex trial design: results and lessons from the abacavir trialAnti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell culturesThe pathogenesis of the neurological complications of HIV-1 infection.Lessons learned developing a diagnostic tool for HIV-associated dementia feasible to implement in resource-limited settings: pilot testing in Kenya.Antiretroviral treatment of central nervous system HIV-1 infection: a review.Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease?Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex.Neuropsychological aspects of HIV infection.Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.Human immunodeficiency virus type 1 infection of the brain.PsychiatryCentral nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugsPersistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.HIV-related neurocognitive impairment--a review.HIV-associated neurological disorders: a guide to pharmacotherapy.Genotypical diversity of HIV clades and central nervous system impairment.Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection.The use of methylphenidate for cognitive decline associated with HIV disease.No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).Neurologic manifestations of HIV infection. Using imaging studies and antiviral therapy effectively.Zidovudine in AIDS dementia complex.Zidovudine in asymptomatic HIV infection: knowledge and uncertainty.Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients.Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.No Neurocognitive Advantage for Immediate Antiretroviral Treatment in adults with greater than 500 CD4+ T Cell Counts.Trends and survival for AIDS patients presenting with indicative neurologic diseases.Impact of current antiretroviral therapies on neuroAIDS
P2860
Q24634681-B607007B-9660-416B-A23D-04F1D03B253DQ28469174-BCCF3B33-0096-4FA3-A697-143E335D364DQ33761961-B6F4D3B7-A836-4360-9834-4982635BEA0EQ33934512-2B38E9CB-1EE1-4FF9-BD2C-FBC0F56B1369Q34193503-712B423C-B540-48FB-9A5E-8F1F851913E2Q34459372-DFB93499-413D-42C9-BFDE-EB23B05A55BDQ35093695-4AB9D1D9-2E6A-409F-8C89-A86DAEFAE749Q35276630-50A08726-9E68-4736-AA95-42383FF6B7B2Q35810392-5F9CFC20-6710-4E75-8480-AD49FBE1A959Q35996765-1764EFC6-25A5-441E-9505-3C9478F0ED49Q36318432-F2311C19-D695-4AB0-888E-4EEC49D5DF9AQ36640545-31FF96B2-A88F-42F4-BEE1-4D3F110A0DFCQ36718237-E08D0967-D4D6-4D6C-9EC6-3F5D2E66869BQ36757759-1AFADE6B-A053-4A05-8DE5-E272565A724DQ37066971-075A5B02-882F-4386-8FF8-C13B17BA317EQ37374348-2D923B71-B8F5-4A29-AB1B-2C1E26CC09BAQ37899895-63535932-4710-4DBB-96D0-5E7194444539Q37971469-2F833904-D47B-48AD-8850-3D1053A04B75Q37980665-6E6236EF-D863-4149-8730-C36D3DD933DFQ38379162-B343A91B-296A-4DD8-86AB-7461D40DA0A7Q40468179-F739FB4C-EE3E-4705-97AB-B2C5B36C574AQ40607244-05437D5A-EB2D-4A44-AAEC-19453900C206Q41728204-464435A2-C9A7-4FE4-B56C-03186B6601E6Q42877932-327EDFB8-1681-4765-B631-8FA182F815EFQ43889558-E6256E5C-0AA1-46DB-A6E2-FBDEBAFB6974Q44582907-BE269234-B9A1-4941-9D61-1058F4864C3FQ46374842-5D8BFB3B-2600-413C-A3A2-CBBA17D9CD0DQ50051625-C5C16F5A-8792-4740-B9B6-AE5643C0BB3CQ54088085-170095F1-BF65-4966-82DF-868E26DE58CCQ57831860-4E03FD8C-0F64-4104-8D5D-C77BB9E14926
P2860
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
description
1989 nî lūn-bûn
@nan
1989 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@ast
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@en
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@nl
type
label
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@ast
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@en
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@nl
prefLabel
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@ast
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@en
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@nl
P2093
P2860
P3181
P356
P1433
P1476
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment
@en
P2093
H Speelman
J Goudsmit
P Portegies
S A Danner
P2860
P304
P3181
P356
10.1136/BMJ.299.6703.819
P407
P577
1989-09-30T00:00:00Z